Better Muscle Mass Linked to Improved Immunotherapy Response

Researchers at Osaka University in Japan have identified a key component of physical health associated with response to immunotherapy drugs. Among people with non-small cell lung cancer, higher levels of muscle mass predicted a better response to PD-1 inhibitor immunotherapy. Sarcopenia — the term used to describe low muscle mass levels — appears to reduce the benefits a person receives from immunotherapy cancer treatment. “Sarcopenia at baseline is a significant predictor of worse outcome in patients with advanced NSCLC [non-small cell lung cancer] receiving PD-1 blockade,” the study investigators wrote. The results, published February 21 in Nature Scientific Reports, highlight the importance of good baseline strength and physical function for mesothelioma patients considering immunotherapy treatments. Immunotherapy is not a standard mesothelioma treatment option. However, there are more than a dozen clinical trials currently investigating PD-1 inhibitor therapy for the asbestos-related cancer. “Screening for sarcopenia may help identify patients more likely to achieve a long-term response in routine clinical practice,” the authors wrote. Strong Body, Stronger Immunotherapy Response Rate Researchers collected information on 42 men and women with non-small cell lung cancer seen at their facility between January 2016 and September 2018. The patients were treated with Opdivo (nivolumab) or Keytruda (pembrolizumab). CT scans available in the ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

Abstract Malignant pleural mesothelioma (MPM) is a remarkably aggressive thoracic malignancy with a limited survival of only 5-12 months. However, MPM still remains unresponsive to conventional standards of treatment, including pleurectomy and decortication, extrapleural pneumonectomy for resectable disease with or without chemotherapy, and/or radiation therapy. The mechanism of carcinogenesis has not been fully elucidated, although approximately 80% of cases can still be linked to asbestos exposure. The tumor immune microenvironment (TME) has been proven to play an important role in MPM pathogenesis and treatment...
Source: Current Drug Targets - Category: Drugs & Pharmacology Authors: Tags: Curr Drug Targets Source Type: research
Patients with pleural mesothelioma cancer may have another treatment option after the U.S. Food and Drug Administration approved the use of pembrolizumab for certain metastatic tumors this week. Pembrolizumab, often known by the brand name Keytruda, is a well-known immunotherapy drug already being used with mixed success for several cancers. This latest FDA approval is for the treatment of adult and pediatric cancers with unresectable disease and high mutational burden that have progressed following prior treatment and have no alternative treatment options. A number of mesothelioma patients already are being treated with p...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Identifying rare subsets of thoracic tumors with gene fusions has redefined therapeutic paradigms. Gene rearrangements involving neurotrophic tropomyosin receptor kinase, (NTRK)1, NTRK2, NTRK3, c-ROS oncogene 1 (ROS1) and the anaplastic lymphoma kinase gene (ALK), result in oncogenic fusion proteins that are detectable using immunohistochemistry screening with variable sensitivity and specificity [1 –3].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
This article is protected by copyright. All rights reserved. PMID: 32437065 [PubMed - as supplied by publisher]
Source: Cell Biology International - Category: Cytology Authors: Tags: Cell Biol Int Source Type: research
Pemetrexed is widely used as an anti-folate cytostatic agent for the treatment of non-small cell lung cancer (NSCLC), mesothelioma and thymoma. [1 –5] Dependent on treatment indication, therapy generally exists of four cycles of induction therapy with pemetrexed and a platinum-agent, which can be combined with the recently approved programmed death-ligand 1 (PD-L1) targeting monoclonal antibody pembrolizumab [6]. Pemetrexed - and, if applica ble, pembrolizumab - can be continued as maintenance treatment following the induction period [3,6].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
ConclusionsThis study indicated that CT ‐707 is clinically effective as a new antitumor drug for Chinese lung adenocarcinoma patients with ALK rearrangement. It is safe and reliable and the dose‐expansion phase recruitment has started.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
The U.S. Food and Drug Administration has granted final approval of Pemfexy, a new brand of the chemotherapy drug pemetrexed, to combat malignant mesothelioma and advanced stage non-small cell lung cancer. The approval will allow oncologists to offer an alternative to Alimta, which today is considered standard pemetrexed and manufactured by Eli Lilly and Company. The chemotherapy drug is designed to block DNA replication and cell division. However, Pemfexy will not be available until February 2022. The FDA approval is limited to pleural mesothelioma patients whose disease is unresectable. Pemfexy is produced by Eagle Pharm...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Although mesothelioma is the consequence of a protracted immune response to asbestos fibers and characterized by a clear immune infiltrate, novel immunotherapy approaches show less convincing results as compared to those seen in melanoma and non-small cell lung cancer. The immune suppressive microenvironment in mesothelioma is likely contributing to this therapy resistance. Therefore, it is important to explore the characteristics of the tumor microenvironment for explanations for this recalcitrant behavior. This review describes the stromal, cytokine, metabolic, and cellular milieu of mesothelioma, and attempts to make co...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
(Impact Journals LLC) Cryopreserved cell-free PE fluid from 101 NSCLC patients, 8 mesothelioma and 13 with benign PE was assayed for a panel of 40 cytokines/chemokines using the Luminex system. Comparing NSCLC PE and published plasma levels of CAR-T recipients, both were dominated by sIL-6R and IL-6 but NSCLC PE had more VEGF, FGF2 and TNF, and less IL-2, IL-4, IL-13, IL-15, MIP1 and IFN.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Conditions:   Non Small Cell Lung Cancer;   Non-squamous Non-small-cell Lung Cancer;   Urothelial Carcinoma;   Malignant Mesothelioma Interventions:   Drug: Cabozantinib;   Drug: Pemetrexed Sponsor:   Augusta University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Asbestosis | Balanced Diets | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | CT Scan | Diets | Environmental Health | Immunotherapy | Japan Health | Lung Cancer | Mesothelioma | Non-Small Cell Lung Cancer | Nutrition | PET Scan | Radiation Therapy | Study | Toxicology | Women